Protagenic Therapeutics Erases $6.3 Million in Liabilities to Advance Promising Depression Treatment
New York, Tuesday, 17 March 2026.
Today, Protagenic Therapeutics eliminated over $6.3 million in liabilities by finalizing its Phytanix separation, allowing the leaner company to focus exclusively on its upcoming Phase 2 clinical trials.
Financial Restructuring and Liability Reduction
The restructuring significantly alters the financial landscape for Protagenic Therapeutics, Inc. (OTCQB: PTIX), a biopharmaceutical firm based in New York City [1]. By separating from Phytanix Bio, the company successfully removed legacy notes, payables, derivative obligations, and related-party balances, shedding more than $6.3 million in liabilities [1][2]. This targeted financial restructuring brings Protagenic’s total liabilities down to approximately $0.5 million, representing a substantial deleveraging of the balance sheet [1]. Furthermore, the company anticipates that the separation will eliminate over $1 million in annualized operational costs previously associated with the Phytanix organization [1][2].
Strategic Pivot Toward PT00114
With a fortified balance sheet and simplified governance, Protagenic Therapeutics is now directing its capital and management resources exclusively toward its primary clinical asset, PT00114 [1][2]. The investigational drug targets the TCAP (teneurin C-terminal associated peptide) pathway and is currently being evaluated for its efficacy in treating treatment-resistant depression, anxiety, and related stress disorders [1]. This strategic pivot follows positive topline safety data gathered from a Phase 1 multiple-dose study, which the company reported in December 2025 [1].